AMGEN INC (AMGN) Factsheet
AMGEN INC (AMGN) Stock Analysis
Analysis from 10-Q filed 2025-11-05. Data as of Q1 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 14.3%. FCF margin 23.1%. D/E 6.2x. Source: 10-Q filed 2025-11-05.
| Metric | Value | Context |
|---|---|---|
| ROIC | 14.3% | Solid returns |
| FCF Margin | 23.1% | Strong cash generation |
| Debt/Equity | 6.2x | Elevated debt |
ROIC 14.3% — Top 25% of sector peers. FCF margin 23.1% — Top 5%.
Explore AMGEN INC: Earnings History | Filings | ROIC Analysis
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for AMGN: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: AMGEN INC earns 14.3% ROIC, Top 25% in Healthcare
ROIC TTM 14.3%, sector median -2.6%, Top 25%. DuPont: NOPAT margin 24.6% × asset turnover 0.4x. Gross margin 68.3%. Operating margin 28.4%. Source: 10-Q filed 2025-11-05.
| Metric | AMGN | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 14.3% | Good | Above sector median of -2.6% |
| Return on Equity (ROE) | 93.4% | Excellent | Efficient use of shareholder equity |
| Gross Margin | 68.3% | Excellent | Strong pricing power |
| Operating Margin | 28.4% | Excellent | Efficient operations |
Cash Flow: AMGEN INC generates $8.6B FCF at 23.1% margin, positive NaN/8 quarters
FCF TTM $8.6B. FCF margin 23.1%, Top 5%. OCF/Net income 1.4x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-11-05.
| Metric | AMGN | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 23.1% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $8.6B | Good | Positive cash generation |
| OCF/Net Income | 1.4x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: AMGEN INC at 6.2x leverage
Debt/Equity 6.2x. Total debt $57.3B, cash & investments $12.0B. Source: 10-Q filed 2025-11-05.
| Metric | AMGN | Rating | Context |
|---|---|---|---|
| Debt to Equity | 6.2x | Red flag | Elevated leverage |
| Net Cash Position | $-45.3B | Warning | Net debt position |
Valuation: AMGEN INC trades at 24.1x earnings
P/E 24.1x. EV/Sales 6.3x. FCF yield 4.6%. Dividend yield 2.8%. Source: 10-Q filed 2025-11-05.
| Metric | AMGN | Rating | Context |
|---|---|---|---|
| P/E Ratio | 24.1x | Adequate | Premium valuation |
| EV/Sales | 6.3x | Adequate | Growth premium priced in |
| FCF Yield | 4.6% | Good | Lower cash yield |
| Dividend Yield | 2.8% | Adequate | Growth focus over income |
Capital Allocation: AMGEN INC returns 2.8% shareholder yield
Total shareholder yield 2.8% (div 2.8%). Capital returned $5.3B TTM. Source: 10-Q filed 2025-11-05.
| Metric | AMGN | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 2.8% | Adequate | Dividend + buyback yield combined |
| Total Capital Returned (TTM) | $5.3B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 14.3% | Top 25% | - |
| Free Cash Flow Margin | 23.1% | Top 5% | - |
| Gross Margin | 68.3% | Top 50% | 1.1x above |
| Operating Margin | 28.4% | Top 25% | 10.6x above |
| Return on Equity (ROE) | 93.4% | Top 5% | - |
| P/E Ratio | 24.1x | N/A | - |
Financial Scorecard
| Metric | AMGN | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 14.3% | Good | Top 25% of sector (median: -2.6%) |
| Free Cash Flow Margin | 23.1% | Excellent | Top 5% of sector (median: 0.0%) |
| Gross Margin | 68.3% | Excellent | Top 50% of sector (median: 63.8%) |
| Debt to Equity Ratio | 623.8% | Red flag | High financial leverage |
| P/E Ratio (Price-to-Earnings) | 24.1x | Adequate | Fair value |
| Free Cash Flow Yield | 4.6% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is AMGEN INC's Return on Invested Capital (ROIC)?
AMGEN INC (AMGN) has a trailing twelve-month Return on Invested Capital (ROIC) of 14.3%. Sector median -2.6%. Source: 10-Q filed 2025-11-05.
Q: What is AMGEN INC's Free Cash Flow Margin?
AMGEN INC (AMGN) has a free cash flow margin of 23.1%, generating $8.6 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-11-05.
Q: What is AMGEN INC's P/E ratio and how does it compare to peers?
AMGEN INC (AMGN) trades at a P/E ratio of 24.1x, which is above the sector median of N/A. EV/Sales 6.3x. FCF yield 4.6%. Source: 10-Q filed 2025-11-05.
Q: Does AMGEN INC pay a dividend?
AMGEN INC (AMGN) currently pays a dividend yield of 2.8%. Total shareholder yield (dividend + buybacks) 2.8%. Source: 10-Q filed 2025-11-05.
Q: How much debt does AMGEN INC have?
AMGEN INC (AMGN) has a debt-to-equity ratio of 6.2x with total debt of $57.3 billion. Net debt $45.3 billion. Source: 10-Q filed 2025-11-05.
Q: What is AMGEN INC's revenue and earnings growth?
AMGEN INC (AMGN) grew revenue by 9.1% year-over-year. EPS +31.2% YoY. Source: 10-Q filed 2025-11-05.
Q: How does AMGEN INC compare to competitors in Healthcare?
Compared to other companies in Healthcare, AMGEN INC (AMGN) shows: ROIC 14.3%, sector median -2.6% (Top 25%). FCF margin 23.1%, sector median 0.0% (Top 5%). Gross margin 68.3%, 4.4pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with AMGEN INC?
Quantitative warning flags for AMGEN INC (AMGN): 1) debt/equity 6.2x (above 1.5x threshold). Source: 10-Q filed 2025-11-05.
Data Source: Data sourced from 10-Q filed 2025-11-05. TTM metrics as of Q1 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.